EXCERPT
– Company plans to build on existing Canadian and U.S. Clozaril® franchise and Canadian breadth of services to physicians and patients
TORONTO and MONTREAL, Sept. 9, 2015 /CNW/ – HLS Therapeutics Inc. (“HLS” or the “Company”), a Canadian specialty pharmaceutical company dedicated to acquiring and marketing legacy branded pharmaceutical drugs, today announced that it together with its affiliates has completed the acquisition of the U.S. and Canadian rights to Clozaril® (clozapine), a pharmaceutical product used in the treatment of schizophrenia. Financial terms were not disclosed.
“We are very excited to formally launch HLS in Canada and in the U.S. as an emerging specialty pharma company with the acquisition of such an important therapy as Clozaril®,” said Greg Gubitz, CEO of HLS. “Our management team’s proven expertise with CNS products will allow HLS to effectively service the needs of schizophrenia patients through continued delivery of the benefits of Clozaril® and its associated programs critical to physicians, patients and pharmacists across the territories. We are 100% committed to ensuring customers and patients have continued and improved access to the best service and care currently available” added Mr. Gubitz.
